Skip to main content

Overview

Skip to main content

SEC Filings Details

Overview

Form 10-K

02/17/2026

Annual Report

PDF Format Download (opens in new window)
Excel Format Download (opens in new window)
XBRL Format Download (opens in new window)
XBRL Format Download (opens in new window)

Contact Us

Tram Bui

Vice President, Investor Relations & Corporate Communications

609-359-3016
tbui@halozyme.com
media@halozyme.com
ir@halozyme.com

Quick Links

SEC Filings
Investor FAQs
Resources

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Halozyme Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Halozyme Therapeutics to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options

Investor Alert Options *

News

Events & Presentations

Quarterly Reports

Annual Reports

SEC Filings

End of Day Stock Quote

Unsubscribe

Email Alert Sign Up Confirmation

Privacy Policy
Cookies Policy

© Q4 Inc. - All rights reserved

Powered By Q4 Inc. 5.178.0.4 (opens in new window)